CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $49.49, moving -0.2% from the previous trading session. This change lagged the S&P 500's 1.7% gain on the day. Elsewhere, the Dow ...

CRISPR Therapeutics AG (CRSP) closed the latest trading day at $49.59, indicating a -0.56% change from the previous session's end. The stock's change was less than the S&P 500's daily loss of 0.29%.

CRISPR Therapeutics' stock may seem boring due to slow FDA trial and rollout process, but it's a strong long-term investment.

Analysts at Precedence Research expect the gene-editing market to grow 15.7% annually and reach $29.9 billion by 2032, ...

CRISPR Therapeutics' first therapy is called Casgevy. It treats sickle cell disease (SCD) and beta thalassemia, both rare inherited illnesses that affect the function of a person's red blood cells. It ...

Crispr Therapeutics 40% share in Casgevy could result in revenue annual between $1.2 billion and $2.8 billion towards the end ...

Given all these factors, it seems reasonable to assume that Casgevy could grab at least a decent share, perhaps 20% of its ...

BMO Capital Markets managing director of biopharma equity research Evan Seigerman joins Market Domination to discuss the best ...

GOVT is a basic U.S. government bond index fund designed to replicate the performance of the ICE U.S. Treasury Core Bond ...

Biotech investing is a thrill-a-minute ride. Biotech stocks can take investors soaring to new heights and fabulous wealth ...

CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

MGK is a passively managed ETF that tracks the performance of the CRSP US Mega Cap Growth index. This index represents the ...